Intech Investment Management LLC Has $14.47 Million Stake in Exelixis, Inc. $EXEL

Intech Investment Management LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 46.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 392,022 shares of the biotechnology company’s stock after purchasing an additional 124,297 shares during the quarter. Intech Investment Management LLC’s holdings in Exelixis were worth $14,473,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of EXEL. Hemington Wealth Management grew its stake in shares of Exelixis by 211.3% in the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 522 shares during the period. Bartlett & CO. Wealth Management LLC bought a new position in Exelixis in the 1st quarter valued at $37,000. Costello Asset Management INC bought a new stake in Exelixis during the 1st quarter worth about $39,000. Harbour Investments Inc. boosted its stake in Exelixis by 900.0% in the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 990 shares during the last quarter. Finally, McIlrath & Eck LLC bought a new stake in Exelixis in the first quarter valued at about $52,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Up 1.6%

Shares of Exelixis stock opened at $38.28 on Wednesday. The stock has a market cap of $10.31 billion, a price-to-earnings ratio of 18.40, a P/E/G ratio of 0.78 and a beta of 0.32. Exelixis, Inc. has a twelve month low of $25.17 and a twelve month high of $49.62. The company’s fifty day moving average is $40.38 and its 200 day moving average is $39.61.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same period last year, the company earned $0.84 earnings per share. The firm’s revenue was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

EXEL has been the subject of a number of research analyst reports. HC Wainwright reduced their target price on shares of Exelixis from $53.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Stephens upgraded Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Truist Financial cut their price objective on shares of Exelixis from $56.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, July 29th. Barclays lifted their price objective on Exelixis from $29.00 to $40.00 and gave the company an “equal weight” rating in a report on Thursday, July 10th. Finally, Wall Street Zen raised shares of Exelixis from a “hold” rating to a “buy” rating in a report on Sunday. Thirteen equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.